Are Occupational Voice Disorders Accurately Measured? A Systematic Review of Prevalence and Methodologies in Schoolteachers to Report Voice Disorders.

Autor: González-Gamboa M; Escuela de Fonoaudiología, Facultad de Salud, Universidad Santo Tomás, Chile. Electronic address: mauriciogonzalezga@santotomas.cl., Segura-Pujol H; Escuela de Fonoaudiología, Facultad de Salud, Universidad Santo Tomás, Chile., Oyarzún PD; Escuela de Fonoaudiología, Facultad de Salud, Universidad Santo Tomás, Chile., Rojas S; Escuela de Fonoaudiología, Facultad de Odontología y Ciencias de la Rehabilitación, Universidad San Sebastián, Santiago, Chile.

Publikováno v: Journal of voice : official journal of the Voice Foundation [J Voice] 2022 Dec 07. Date of Electronic Publication: 2022 Dec 07.

Rethinking the use of urine dipstick for early diagnosis of Type 2 diabetes mellitus.

Autor: Jensen OC; Centre for Maritime Health and Society, Department of Public Health, University of Southern Denmark, Degnevej 14, 6705 Esbjerg, Denmark; University of Cadiz FUECA, Spain. Electronic address: ocj@health.sdu.dk., Flores A; Universidad Metropolitana de Educación Ciencia y Tecnología, Facultad de las Ciencias y Tecnología, Panamá & Caja Seguro Social, Vacamonte Rep. of Panamá, Panama., Corman V; Department of Public Health, University of Southern Denmark, Esbjerg, Denmark. Electronic address: vicor20@student.sdu.dk., Luisa Canals M; University of Cadiz FUECA, Spain; Sociedad Española de Medicina Marítima (SEMM) /Sanidad Marítima, Tarragona, Spain; Sanidad Maritima (ISM), Barcelona, Spain., Lucas D; ORPHY Laboratory, University Brest, F-29200 Brest, France; Occupational and Environmental Diseases Center, Teaching Hospital, F-29200 Brest, France; French Society of Maritime Medicine Brest, F-29200, France. Electronic address: lucas_d29@yahoo.fr., Denisenko I; Regional Medical Office German Embassy Moscow, Russia., Lucero-Prisno DE; Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, United Kingdom; Faculty of Management and Development Studies, University of the Philippines Open University, Los Baños, Laguna, Philippines. Electronic address: don-eliseo.lucero-prisno@lshtm.ac.uk., Lilja Secher A; Clinical Research, Steno Diabetes Center Copenhagen, Denmark. Electronic address: anna.elisabet.lilja.secher@regionh.dk., Stig Andersen G; Clinical Research, Steno Diabetes Center Copenhagen, Denmark. Electronic address: gregers.stig.andersen@regionh.dk., Eika Jørgensen M; Clinical Research, Steno Diabetes Center Greenland, Greenland. Electronic address: maej@peqqik.gl., Estopà Pujol H; Sociedad Española de Medicina Marítima (SEMM) /Sanidad Marítima, Tarragona, Spain; Sanidad Maritima (ISM), Barcelona, Spain. Electronic address: helena.estopa@seg-social.es., Cohen G; Faculty of Medicine, Panama University, Rep. of Panamá., Gyntelberg F; National Research Center for Work Environment & Occup. Med. Clinic, Bispebjerg Hospital, Denmark.

Publikováno v: Diabetes research and clinical practice [Diabetes Res Clin Pract] 2022 Feb; Vol. 184, pp. 109222. Date of Electronic Publication: 2022 Jan 31.

Chemotherapy in carcinomas of unknown primary site: A high-dose intensity policy

Autor: Culine, S. ^*, Fabbro, M., Ychou, M., Romieu, G., Cupissol, D., Pujol, H.

Publikováno v: In Annals of Oncology May 1999 10(5):569-576

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator.

Autor: Jimenez E; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, 08020, Barcelona, Spain. lali.jimenez@astrazeneca.com., Astbury C; Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain., Albayaty M; Early Phase Clinical Unit, PAREXEL International GmbH, Harrow, UK., Wählby-Hamrén U; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Seoane B; Biometrics and Information Sciences, Late-Stage Development, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain., Villarroel C; Late-Stage Development, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain., Pujol H; Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain., Bermejo MJ; Patient Safety, Chief Medical Office, R&D, AstraZeneca, Barcelona, Spain., Aggarwal A; Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain., Psallidas I; Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Publikováno v: Respiratory research [Respir Res] 2020 Sep 09; Vol. 21 (Suppl 1), pp. 211. Date of Electronic Publication: 2020 Sep 09.